PRINCETON, N.J.--(BUSINESS WIRE)--PharmaNet Development Group, Inc. (NASDAQ: PDGI), a leading provider of drug development services to branded pharmaceutical, biotechnology, generic drug and medical device companies, today reported GAAP net earnings from continuing operations for its fourth quarter 2006 of $3.5 million ($0.19 per diluted share) and for the full year ended December 31, 2006 of $6.1 million ($0.33 per diluted share).
